Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Performance of Diabetes Screening Tests: An Evaluation Study of Iranian Diabetes Screening Program

Version 1 : Received: 28 September 2020 / Approved: 29 September 2020 / Online: 29 September 2020 (15:12:26 CEST)

How to cite: Kianpour, F.; Fararouei, M.; Hassanzadeh, J.; Mohammadi, M.; Dianatinasab, M. Performance of Diabetes Screening Tests: An Evaluation Study of Iranian Diabetes Screening Program. Preprints 2020, 2020090719 (doi: 10.20944/preprints202009.0719.v1). Kianpour, F.; Fararouei, M.; Hassanzadeh, J.; Mohammadi, M.; Dianatinasab, M. Performance of Diabetes Screening Tests: An Evaluation Study of Iranian Diabetes Screening Program. Preprints 2020, 2020090719 (doi: 10.20944/preprints202009.0719.v1).

Abstract

Background: Diabetes is a common non-communicable disease that is responsible for about 9% of all deaths and 25% reduction in life expectancy and nearly half of the diabetic patients are not aware of their disease. In this regard, diabetes screening to identify un-known diabetic patients is of great importance. Aims: The aims of this study were first to evaluate the performance of two commonly used diabetes screening tests that are currently recommended by the Iranian national screening program for diabetes (NSPD). Methods: The validities of the two diabetes screening tests were measured among 1057 participants older than 30 years. The studied screening tests included Capillary fasting blood glucose (CBG) and glycated hemoglobin (HbA1c). The golden standard for measuring the validity of the tests was venous fasting plasma glucose (VPG). Results: According to the results, the sensitivity of CBG and HbA1c tests were 69.01% and 84.5% and the specificity of the tests were 95.7% and 79.3% respectively. Positive and negative predictive values were 53.84% and 97.72% for CBG and 22.72% and 98.61% for HbA1c respectively. The recommended cut-points for CBG and HbA1c were 116.5 mg/dl and 7.15% respectively. Using these values as the new cut-points, sensitivity and specificity of CBG and HbA1c changed to 80.30% and 89.10%, and 77.50% and 94.20% respectively. Conclusions: Compared to several other countries, the performance of NSPD is relatively higher in Iran. ROC analysis suggested new cut-points for significantly better performance of NSPD.

Subject Areas

Diabetes mellitus, screening, HbA1c, fasting plasma glucose

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.